-
1
-
-
37349020028
-
Hepatitis C: A clinical review
-
DOI 10.1111/j.1601-0825.2007.01419.x
-
Modi, A.A. & Liang, T.J. Hepatitis C: a clinical review. Oral Dis. 14, 10-14 (2008). (Pubitemid 350293995)
-
(2008)
Oral Diseases
, vol.14
, Issue.1
, pp. 10-14
-
-
Modi, A.A.1
Liang, T.J.2
-
2
-
-
0032475822
-
Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy
-
DOI 10.1126/science.282.5386.103
-
Neumann, A.U. et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282, 103-107 (1998). (Pubitemid 28471138)
-
(1998)
Science
, vol.282
, Issue.5386
, pp. 103-107
-
-
Neumann, A.U.1
Lam, N.P.2
Dahari, H.3
Gretch, D.R.4
Wiley, T.E.5
Layden, T.J.6
Perelson, A.S.7
-
3
-
-
79953009968
-
-
Centers for Disease Control and Prevention and Department of Health and Human Services CDC and HHS
-
Centers for Disease Control and Prevention and Department of Health and Human Services. Hepatitis C fact sheet (CDC and HHS, 2010). 〈http://www. cdc.gov/hepatitis/HCV/PDFs/HepCGeneralFactSheet.pdf〉
-
(2010)
Hepatitis C Fact Sheet
-
-
-
4
-
-
73149113990
-
Public health impact of antiviral therapy for hepatitis C in the United States
-
Volk, M.L., Tocco, R., Saini, S. & Lok, A. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 50, 1750-1755 (2009).
-
(2009)
Hepatology
, vol.50
, pp. 1750-1755
-
-
Volk, M.L.1
Tocco, R.2
Saini, S.3
Lok, A.4
-
5
-
-
77950611229
-
Institute of Medicine recommendations for the prevention and control of hepatitis B and C
-
Mitchell, A.E., Colvin, H.M. & Palmer Beasley, R. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology 51, 729-733 (2010).
-
(2010)
Hepatology
, vol.51
, pp. 729-733
-
-
Mitchell, A.E.1
Colvin, H.M.2
Palmer Beasley, R.3
-
7
-
-
0032934283
-
Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy
-
DOI 10.1002/hep.510290124
-
Bonkovsky, H. & Woolley, J. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology 29, 264-270 (1999). (Pubitemid 29024012)
-
(1999)
Hepatology
, vol.29
, Issue.1
, pp. 264-270
-
-
Bonkovsky, H.L.1
Wolley, M.2
-
8
-
-
11144356775
-
Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients
-
DOI 10.1016/j.jhep.2004.01.005, PII S0168827804000145
-
Planas, R. et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J. Hepatol. 40, 823-830 (2004). (Pubitemid 38507364)
-
(2004)
Journal of Hepatology
, vol.40
, Issue.5
, pp. 823-830
-
-
Planas, R.1
Balleste, B.2
Alvarez, M.A.3
Rivera, M.4
Montoliu, S.5
Galeras, J.A.6
Santos, J.7
Coll, S.8
Maria Morillas, R.9
Sola, R.10
-
9
-
-
33644520948
-
Therapy of hepatitis C: From empiricism to eradication
-
Pawlotsky, J.M. Therapy of hepatitis C: from empiricism to eradication. Hepatology 43, S207-S220 (2006).
-
(2006)
Hepatology
, vol.43
-
-
Pawlotsky, J.M.1
-
10
-
-
65449136656
-
Diagnosis management, and treatment of hepatitis C: An update
-
Ghany, M.G., Strader, D.B., Thomas, D.L. & Seeff, L.B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49, 1335-1374 (2009).
-
(2009)
Hepatology
, vol.49
, pp. 1335-1374
-
-
Ghany, M.G.1
Strader, D.B.2
Thomas, D.L.3
Seeff, L.B.4
-
11
-
-
78650741799
-
Current therapies for chronic hepatitis C
-
Ferguson, M. Current therapies for chronic hepatitis C. Pharmacotherapy 31, 92-111 (2011).
-
(2011)
Pharmacotherapy
, vol.31
, pp. 92-111
-
-
Ferguson, M.1
-
12
-
-
34250679750
-
Epidemiology of hepatitis C virus infection
-
Alter, M.J. Epidemiology of hepatitis C virus infection. World J. Gastroenterol. 13, 2436-2441 (2007). (Pubitemid 46929498)
-
(2007)
World Journal of Gastroenterology
, vol.13
, Issue.17
, pp. 2436-2441
-
-
Alter, M.J.1
-
13
-
-
0035934568
-
Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
-
DOI 10.1016/S0140-6736(01)06102-5
-
Manns, M.P. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958-965 (2001). (Pubitemid 32913521)
-
(2001)
Lancet
, vol.358
, Issue.9286
, pp. 958-965
-
-
Manns, M.P.1
McHutchison, J.G.2
Gordon, S.C.3
Rustgi, V.K.4
Shiffman, M.5
Reindollar, R.6
Goodman, Z.D.7
Koury, K.8
Ling, M.-H.9
Albrecht, J.K.10
-
14
-
-
0037179698
-
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
-
Fried, M.W. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347, 975-982 (2002).
-
(2002)
N. Engl. J. Med.
, vol.347
, pp. 975-982
-
-
Fried, M.W.1
-
15
-
-
33747797031
-
Treating viral hepatitis C: Efficacy, side effects, and complications
-
DOI 10.1136/gut.2005.076646
-
Manns, M., Wedemeyer, H. & Cornberg, M. Treating viral hepatitis C: efficacy, side effects and complications. Gut 55, 1350-1359 (2006). (Pubitemid 44277369)
-
(2006)
Gut
, vol.55
, Issue.9
, pp. 1350-1359
-
-
Manns, M.P.1
Wedemeyer, H.2
Cornberg, M.3
-
16
-
-
84858446874
-
-
Hoffmann-La Roche, Providence, RI
-
Pegasys (prescribing information) (Hoffmann-La Roche, Providence, RI, 2011). 〈http://www.gene.com/gene/products/information/pegasys/pdf/pi. pdf〉
-
(2011)
Pegasys (Prescribing Information)
-
-
-
17
-
-
84858449936
-
-
Merck & Co, Whitehouse Station, NJ, USA
-
Pegintron (prescribing information). (Merck & Co, Whitehouse Station, NJ, USA, 2011). 〈http://www.spfiles.com/pipeg-intron.pdf〉
-
(2011)
Pegintron (Prescribing Information)
-
-
-
18
-
-
1542378867
-
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose
-
Hadziyannis, S.J. et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140, 346-355 (2004).
-
(2004)
Ann. Intern. Med.
, vol.140
, pp. 346-355
-
-
Hadziyannis, S.J.1
-
19
-
-
65449152185
-
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection
-
erratum, 361 1516 2009
-
McHutchison, J.G. et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 360, 1827-1838 (2009); erratum, 361, 1516 (2009).
-
(2009)
N. Engl. J. Med.
, vol.360
, pp. 1827-1838
-
-
McHutchison, J.G.1
-
20
-
-
66949176133
-
Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results
-
Bacon, B.R. et al. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology 49, 1838-1846 (2009).
-
(2009)
Hepatology
, vol.49
, pp. 1838-1846
-
-
Bacon, B.R.1
-
21
-
-
65349129985
-
Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-?2b: A randomized trial
-
Jensen, D.M. et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-?2b: a randomized trial. Ann. Intern. Med. 150, 528-540 (2009).
-
(2009)
Ann. Intern. Med.
, vol.150
, pp. 528-540
-
-
Jensen, D.M.1
-
22
-
-
67349172961
-
Peginterferon alfa-2b and ribavirin: Effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy
-
Poynard, T. et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 136, 1618-1628 (2009).
-
(2009)
Gastroenterology
, vol.136
, pp. 1618-1628
-
-
Poynard, T.1
-
23
-
-
38449091418
-
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis
-
Veldt, B., Heathcote, J. & Wedmeyer, H. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann. Intern. Med. 147, 677-684 (2007). (Pubitemid 351664462)
-
(2007)
Annals of Internal Medicine
, vol.147
, Issue.10
, pp. 677-684
-
-
Veldt, B.J.1
Heathcote, E.J.2
Wedemeyer, H.3
Reichen, J.4
Hofmann, W.P.5
Zeuzem, S.6
Manns, M.P.7
Hansen, B.E.8
Schalm, S.W.9
Janssen, H.L.A.10
-
24
-
-
80755161906
-
Outcome of sustained virological responders and non-responders in the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial
-
Morgan, T.R. et al. Outcome of sustained virological responders and non-responders in the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology 50 Suppl, 357A-358A (2009).
-
(2009)
Hepatology
, vol.50
, Issue.SUPPL.
-
-
Morgan, T.R.1
-
25
-
-
77952704228
-
Sustained virologic response prevents the development of esophageal varices in compensated Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study
-
Bruno, S. et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology 51, 2069-2076 (2010).
-
(2010)
Hepatology
, vol.51
, pp. 2069-2076
-
-
Bruno, S.1
-
26
-
-
79953745558
-
Impact of sustained virologic response to pegylated interferon/ribavirin on all-cause mortality by HCV genotype in a large real-world cohort: The US Department of Veterans Affairs' experience
-
Backus, L. et al. Impact of sustained virologic response to pegylated interferon/ribavirin on all-cause mortality by HCV genotype in a large real-world cohort: the US Department of Veterans Affairs' experience. Hepatology 52 Suppl, 428A (2010).
-
(2010)
Hepatology
, vol.52
, Issue.SUPPL.
-
-
Backus, L.1
-
27
-
-
0000163169
-
Flaviviridae the viruses and their replication
-
(eds. Knipe, D.M. et al.) Lippincott Williams & Wilkins, Philadelphia
-
Lindenbach, B.D. & Rice, C.M. Flaviviridae: the viruses and their replication. in Field's Virology, ed. 4. (eds. Knipe, D.M. et al.) 991-1041 (Lippincott Williams & Wilkins, Philadelphia, 2001).
-
(2001)
Field's Virology
, vol.4
, pp. 991-1041
-
-
Lindenbach, B.D.1
Rice, C.M.2
-
28
-
-
23944476834
-
Unravelling hepatitis C virus replication from genome to function
-
DOI 10.1038/nature04077
-
Lindenbach, B.D. & Rice, C.M. Unravelling hepatitis C virus replication: from genome to function. Nature 436, 933-938 (2005). (Pubitemid 41191668)
-
(2005)
Nature
, vol.436
, Issue.7053
, pp. 933-938
-
-
Lindenbach, B.D.1
Rice, C.M.2
-
29
-
-
84858437985
-
-
Vertex Pharmaceuticals
-
Incivek (US package insert) (Vertex Pharmaceuticals, 2011). 〈http://pi.vrtx.com/files/uspi-telaprevir.pdf〉
-
(2011)
Incivek (US Package Insert)
-
-
-
30
-
-
84858440209
-
-
Vertex Pharmaceuticals
-
Incivek (Canada product monograph) (Vertex Pharmaceuticals, 2011). 〈http://pi.vrtx. com/files/canadapm-telaprevir-en.pdf〉.
-
(2011)
Incivek (Canada Product Monograph)
-
-
-
31
-
-
84929133500
-
-
Tibotec, Beerse, Belgium
-
Incivo (EU summary of product characteristics) (Tibotec, Beerse, Belgium, 2011). 〈http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/002313/WC500115529.pdf〉.
-
(2011)
Incivo (EU Summary of Product Characteristics)
-
-
-
32
-
-
84858444945
-
-
Mitsubishi Tanabe Pharma, Osaka, Japan
-
Telavic (Japan package insert). (Mitsubishi Tanabe Pharma, Osaka, Japan, 2011). 〈http://www.mt-pharma.co.jp/e/release/nr/2011/pdf/eMTPC110926-TLV. pdf〉
-
(2011)
Telavic (Japan Package Insert)
-
-
-
33
-
-
1842632416
-
Population-Based Hepatitis C Surveillance and Treatment in a National Managed Care Organization
-
Shatin, D., Schech, S.D., Patel, K. & McHutchison, J.G. Population-based hepatitis C surveillance and treatment in a national managed care organization. Am. J. Manag. Care 10, 250-256 (2004). (Pubitemid 38480794)
-
(2004)
American Journal of Managed Care
, vol.10
, Issue.4
, pp. 250-256
-
-
Shatin, D.1
Schech, S.D.2
Patel, K.3
McHutchison, J.G.4
-
34
-
-
78649461752
-
-
Milliman, Inc.
-
Pyenson, B., Fitch, K. & Iwasaki, K. Consequences of Hepatitis C Virus (HCV): Costs of a Baby Boomer Epidemic of Liver Disease (Milliman, Inc., 2009).
-
(2009)
Consequences of Hepatitis C Virus (HCV): Costs of A Baby Boomer Epidemic of Liver Disease
-
-
Pyenson, B.1
Fitch, K.2
Iwasaki, K.3
-
35
-
-
75149163334
-
Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression
-
Davis, G.L., Alter, M.J., El-Serag, H., Poynard, T. & Jennings, L.W. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138, 513-521 (2010).
-
(2010)
Gastroenterology
, vol.138
, pp. 513-521
-
-
Davis, G.L.1
Alter, M.J.2
El-Serag, H.3
Poynard, T.4
Jennings, L.W.5
-
36
-
-
0036982198
-
Inhibitors of hepatitis C virus NS3.4A protease: An overdue line of therapy
-
Perni, R.B. & Kwong, A.D. Inhibitors of hepatitis C virus NS3.4A protease: an overdue line of therapy. Prog. Med. Chem. 39, 215-255 (2002).
-
(2002)
Prog. Med. Chem.
, vol.39
, pp. 215-255
-
-
Perni, R.B.1
Kwong, A.D.2
-
37
-
-
78650021698
-
Recent advances in hepatitis C virus treatment: Review of HCV protease inhibitor clinical trials
-
Chary, A. & Holodniy, M. Recent advances in hepatitis C virus treatment: review of HCV protease inhibitor clinical trials. Rev. Recent Clin. Trials 5, 158-173 (2010).
-
(2010)
Rev. Recent Clin. Trials
, vol.5
, pp. 158-173
-
-
Chary, A.1
Holodniy, M.2
-
38
-
-
84939257725
-
Recent progress in the development of HCV protease inhibitors
-
(ed. De Clercq, E.) Wiley-VCH, Weinheim, Germany
-
Mani, N., Rao, B.G., Kieffer, T.L. & Kwong, A.D. Recent progress in the development of HCV protease inhibitors. in Antiviral Drug Strategies (ed. De Clercq, E.) 307-328 (Wiley-VCH, Weinheim, Germany, 2011).
-
(2011)
Antiviral Drug Strategies
, pp. 307-328
-
-
Mani, N.1
Rao, B.G.2
Kieffer, T.L.3
Kwong, A.D.4
-
39
-
-
79953905045
-
Nonstructural protein 3-4A: The Swiss army knife of hepatitis C virus
-
Morikawa, K. et al. Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus. J. Viral Hepat. 18, 305-315 (2011).
-
(2011)
J. Viral Hepat.
, vol.18
, pp. 305-315
-
-
Morikawa, K.1
-
40
-
-
68249161340
-
Serine protease inhibitors as anti-hepatitis C virus agents
-
R eiser, M. & Timm, J. Serine protease inhibitors as anti-hepatitis C virus agents. Expert Rev. Anti Infect. Ther. 7, 537-547 (2009).
-
(2009)
Expert Rev. Anti Infect. Ther.
, vol.7
, pp. 537-547
-
-
Reiser, M.1
Timm, J.2
-
44
-
-
78650988631
-
Mixing the right hepatitis C inhibitor cocktail
-
Gelman, A. & Glenn, J. Mixing the right hepatitis C inhibitor cocktail. Trends Mol. Med. 17, 34-46 (2011).
-
(2011)
Trends Mol. Med.
, vol.17
, pp. 34-46
-
-
Gelman, A.1
Glenn, J.2
-
45
-
-
79952804270
-
Promising targets for anti-hepatitis C virus agents
-
Yoshida, T., Kondoh, M. & Yagi, K. Promising targets for anti-hepatitis C virus agents. Curr. Med. Chem. 18, 1239-1244 (2011).
-
(2011)
Curr. Med. Chem.
, vol.18
, pp. 1239-1244
-
-
Yoshida, T.1
Kondoh, M.2
Yagi, K.3
-
46
-
-
78149425102
-
Antiviral therapy for hepatitis C virus: Beyond the standard of care
-
Delang, L., Coelmont, L. & Neyts, J. Antiviral therapy for hepatitis C virus: beyond the standard of care. Viruses 2, 826-866 (2010).
-
(2010)
Viruses
, vol.2
, pp. 826-866
-
-
Delang, L.1
Coelmont, L.2
Neyts, J.3
-
47
-
-
0028908783
-
Substrate determinants for cleavage in cis and in trans by the hepatitis C virus NS3 proteinase
-
Bartenschlager, R., Ahlborn-Laake, L., Yasargil, K., Mous, J. & Jacobsen, H. Substrate determinants for cleavage in cis and in trans by the hepatitis C virus NS3 proteinase. J. Virol. 69, 198-205 (1995). (Pubitemid 24378794)
-
(1995)
Journal of Virology
, vol.69
, Issue.1
, pp. 198-205
-
-
Bartenschlager, R.1
Ahlborn-Laake, L.2
Yasargil, K.3
Mous, J.4
Jacobsen, H.5
-
48
-
-
0033072323
-
Hepatitis C virus NS3/4A protease
-
Kwong, A.D., Kim, J.L., Rao, G., Lipovsek, D. & Raybuck, S.A. Hepatitis C virus NS3/4A protease. Antiviral Res. 41, 67-84 (1999).
-
(1999)
Antiviral Res.
, vol.41
, pp. 67-84
-
-
Kwong, A.D.1
Kim, J.L.2
Rao, G.3
Lipovsek, D.4
Raybuck, S.A.5
-
49
-
-
16044364658
-
Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide
-
DOI 10.1016/S0092-8674(00)81351-3
-
Kim, J.L. et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87, 343-355 (1996). (Pubitemid 26359011)
-
(1996)
Cell
, vol.87
, Issue.2
, pp. 343-355
-
-
Kim, J.L.1
Morgenstern, K.A.2
Lin, C.3
Fox, T.4
Dwyer, M.D.5
Landro, J.A.6
Chambers, S.P.7
Markland, W.8
Lepre, C.A.9
O'Malley, E.T.10
Harbeson, S.L.11
Rice, C.M.12
Murcko, M.A.13
Caron, P.R.14
Thomson, J.A.15
-
50
-
-
0030592514
-
The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site
-
DOI 10.1016/S0092-8674(00)81350-1
-
Love, R.A. et al. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 87, 331-342 (1996). (Pubitemid 26359010)
-
(1996)
Cell
, vol.87
, Issue.2
, pp. 331-342
-
-
Love, R.A.1
Parge, H.E.2
Wickersham, J.A.3
Hostomsky, Z.4
Habuka, N.5
Moomaw, E.W.6
Adachi, T.7
Hostomska, Z.8
-
51
-
-
0032424249
-
Rational design and functional expression of a constitutively active single-chain NS4A-NS3 proteinase
-
DOI 10.1016/S1359-0278(98)00060-1
-
Pasquo, A. et al. Rational design and functional expression of a constitutively active single-chain NS4A-NS3 proteinase. Fold. Des. 3, 433-441 (1998). (Pubitemid 29023609)
-
(1998)
Folding and Design
, vol.3
, Issue.6
, pp. 433-441
-
-
Pasquo, A.1
Nardi, M.C.2
Dimasi, N.3
Tomei, L.4
Steinkuhler, C.5
Delmastro, P.6
Tramontano, A.7
De Francesco, R.8
-
52
-
-
0031789165
-
Construction, expression, and characterization of a novel fully activated recombinant single-chain hepatitis C virus protease
-
Taremi, S.S. et al. Construction, expression, and characterization of a novel fully activated recombinant single-chain hepatitis C virus protease. Protein Sci. 7, 2143-2149 (1998). (Pubitemid 28495801)
-
(1998)
Protein Science
, vol.7
, Issue.10
, pp. 2143-2149
-
-
Taremi, S.S.1
Beyer, B.2
Maher, M.3
Yao, N.4
Prosise, W.5
Weber, P.C.6
Malcolm, B.A.7
-
53
-
-
0033571623
-
Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase
-
DOI 10.1016/S0969-2126(00)80025-8
-
Yao, N., Reichert, P., Taremi, S.S., Prosise, W.W. & Weber, P.C. Molecular views of the viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure 7, 1353-1363 (1999). (Pubitemid 29529876)
-
(1999)
Structure
, vol.7
, Issue.11
, pp. 1353-1363
-
-
Yao, N.1
Reichert, P.2
Taremi, S.S.3
Prosise, W.W.4
Weber, P.C.5
-
54
-
-
0036835773
-
Hepatitis C virus replicons: Potential role for drug development
-
DOI 10.1038/nrd942
-
Bartenschlager, R. Hepatitis C virus replicons: potential role for drug development. Nat. Rev. Drug Discov. 1, 911-916 (2002). (Pubitemid 37361585)
-
(2002)
Nature Reviews Drug Discovery
, vol.1
, Issue.11
, pp. 911-916
-
-
Bartenschlager, R.1
-
55
-
-
0345188811
-
Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line
-
DOI 10.1126/science.285.5424.110
-
Lohmann, V. et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285, 110-113 (1999). (Pubitemid 29307577)
-
(1999)
Science
, vol.285
, Issue.5424
, pp. 110-113
-
-
Lohmann, V.1
Korner, F.2
Koch, J.-O.3
Herian, U.4
Theilmann, L.5
Bartenschlager, R.6
-
56
-
-
33644636312
-
Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease
-
DOI 10.1128/AAC.50.3.899-909.2006
-
Perni, R.B. et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob. Agents Chemother. 50, 899-909 (2006). (Pubitemid 43327793)
-
(2006)
Antimicrobial Agents and Chemotherapy
, vol.50
, Issue.3
, pp. 899-909
-
-
Perni, R.B.1
Almquist, S.J.2
Byrn, R.A.3
Chandorkar, G.4
Chaturvedi, P.R.5
Courtney, L.F.6
Decker, C.J.7
Dinehart, K.8
Gates, C.A.9
Harbeson, S.L.10
Heiser, A.11
Kalkeri, G.12
Kolaczkowski, E.13
Lin, K.14
Luong, Y.-P.15
Rao, B.G.16
Taylor, W.P.17
Thomson, J.A.18
Tung, R.D.19
Wei, Y.20
Kwong, A.D.21
Lin, C.22
more..
-
57
-
-
84885968342
-
Discovery and development of telaprevir
-
(ed., Kazmierski, W.) John Wiley & Sons
-
Grillot, A. et al. Discovery and development of telaprevir. in Antiviral Drugs: from Basic Discovery through Clinical Trials (ed., Kazmierski, W.) 209-224 (John Wiley & Sons, 2010.)
-
(2010)
Antiviral Drugs: From Basic Discovery Through Clinical Trials
, pp. 209-224
-
-
Grillot, A.1
-
58
-
-
15944372847
-
Expression of HCV protease in mouse liver results in liver injury which can be inhibited by VX-950, a Vertex HCV protease inhibitor
-
Kalkeri, G. et al. Expression of HCV protease in mouse liver results in liver injury which can be inhibited by VX-950, a Vertex HCV protease inhibitor. Hepatology 40 Suppl, 281A (2004).
-
(2004)
Hepatology
, vol.40
, Issue.SUPPL.
-
-
Kalkeri, G.1
-
59
-
-
24944472318
-
Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infection
-
Chen, S.H. & Tan, S.L. Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infection. Curr. Med. Chem. 12, 2317-2342 (2005).
-
(2005)
Curr. Med. Chem.
, vol.12
, pp. 2317-2342
-
-
Chen, S.H.1
Tan, S.L.2
-
60
-
-
33744457959
-
Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease
-
Lin, C., Kwong, A.D. & Perni, R.B. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect. Disord. Drug Targets 6, 3-16 (2006). (Pubitemid 43796632)
-
(2006)
Infectious Disorders - Drug Targets
, vol.6
, Issue.1
, pp. 3-16
-
-
Lin, C.1
Kwong, A.D.2
Perni, R.B.3
-
61
-
-
0347809950
-
Inhibitors of hepatitis C virus NS3-4A protease 1. Non-charged tetrapeptide variants
-
DOI 10.1016/j.bmcl.2003.08.050
-
Perni, R.B. et al. Inhibitors of hepatitis C virus NS3-4A protease 1. Non-Charged tetrapeptide variants. Bioorg. Med. Chem. Lett. 13, 4059-4063 (2003). (Pubitemid 37338448)
-
(2003)
Bioorganic and Medicinal Chemistry Letters
, vol.13
, Issue.22
, pp. 4059-4063
-
-
Perni, R.B.1
Britt, S.D.2
Court, J.C.3
Courtney, L.F.4
Deininger, D.D.5
Farmer, L.J.6
Gates, C.A.7
Harbeson, S.L.8
Kim, J.L.9
Landro, J.A.10
Levin, R.B.11
Luong, Y.-P.12
O'Malley, E.T.13
Pitlik, J.14
Rao, B.G.15
Schairer, W.C.16
Thomson, J.A.17
Tung, R.D.18
Van Drie, J.H.19
Wei, Y.20
more..
-
62
-
-
12144286493
-
2 proline variants
-
DOI 10.1016/j.bmcl.2004.01.078, PII S0960894X04001581
-
Perni, R.B. et al. Inhibitors of hepatitis C virus NS3-4A protease 3. P2 Proline Variants. Bioorg. Med. Chem. Lett. 14, 1939-1942 (2004). (Pubitemid 38410868)
-
(2004)
Bioorganic and Medicinal Chemistry Letters
, vol.14
, Issue.8
, pp. 1939-1942
-
-
Perni, R.B.1
Farmer, L.J.2
Cottrell, K.M.3
Court, J.J.4
Courtney, L.F.5
Deininger, D.D.6
Gates, C.A.7
Harbeson, S.L.8
Kim, J.L.9
Lin, C.10
Lin, K.11
Luong, Y.-P.12
Maxwell, J.P.13
Murcko, M.A.14
Pitlik, J.15
Rao, B.G.16
Schairer, W.C.17
Tung, R.D.18
Van Drie, J.H.19
Wilson, K.20
Thomson, J.A.21
more..
-
63
-
-
10744231857
-
Inhibitors of hepatitis C virus NS3-4A protease 2. Warhead SAR and optimization
-
DOI 10.1016/j.bmcl.2004.01.022, PII S0960894X04000721
-
Perni, R.B. et al. Inhibitors of hepatitis C virus NS3-4A protease 2. Warhead SAR and optimization. Bioorg. Med. Chem. Lett. 14, 1441-1446 (2004). (Pubitemid 38299426)
-
(2004)
Bioorganic and Medicinal Chemistry Letters
, vol.14
, Issue.6
, pp. 1441-1446
-
-
Perni, R.B.1
Pitlik, J.2
Britt, S.D.3
Court, J.J.4
Courtney, L.F.5
Deininger, D.D.6
Farmer, L.J.7
Gates, C.A.8
Harbeson, S.L.9
Levin, R.B.10
Lin, C.11
Lin, K.12
Moon, Y.-C.13
Luong, Y.-P.14
O'Malley, E.T.15
Rao, B.G.16
Thomson, J.A.17
Tung, R.D.18
Van Drie, J.H.19
Wei, Y.20
more..
-
64
-
-
34249297393
-
Inhibitors of hepatitis C virus NS3-4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokinetics
-
DOI 10.1016/j.bmcl.2007.03.090, PII S0960894X07004039
-
Perni, R.B. et al. Inhibitors of hepatitis C virus NS3.4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokinetics. Bioorg. Med. Chem. Lett. 17, 3406-3411 (2007). (Pubitemid 46819020)
-
(2007)
Bioorganic and Medicinal Chemistry Letters
, vol.17
, Issue.12
, pp. 3406-3411
-
-
Perni, R.B.1
Chandorkar, G.2
Cottrell, K.M.3
Gates, C.A.4
Lin, C.5
Lin, K.6
Luong, Y.-P.7
Maxwell, J.P.8
Murcko, M.A.9
Pitlik, J.10
Rao, G.11
Schairer, W.C.12
Drie, J.V.13
Wei, Y.14
-
65
-
-
0030871616
-
Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: Elucidation of the NS4A stimulatory effect via kinetic analysis and inhibitor mapping
-
DOI 10.1021/bi963054n
-
Landro, J.A. et al. Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: elucidation of the NS4A stimulatory effect via kinetic analysis and inhibitor mapping. Biochemistry 36, 9340-9348 (1997). (Pubitemid 27346971)
-
(1997)
Biochemistry
, vol.36
, Issue.31
, pp. 9340-9348
-
-
Landro, J.A.1
Raybuck, S.A.2
Luong, Y.P.C.3
O'Malley, E.T.4
Harbeson, S.L.5
Morgenstern, K.A.6
Rao, G.7
Livingston, D.J.8
-
66
-
-
0032493405
-
Peptide-based inhibitors of the hepatitis C virus serine protease
-
DOI 10.1016/S0960-894X(98)00299-6, PII S0960894X98002996
-
Llinas-Brunet, M. et al. Peptide-based inhibitors of the hepatitis C virus serine protease. Bioorg. Med. Chem. Lett. 8, 1713-1718 (1998). (Pubitemid 28341617)
-
(1998)
Bioorganic and Medicinal Chemistry Letters
, vol.8
, Issue.13
, pp. 1713-1718
-
-
Llinas-Brunet, M.1
Bailey, M.2
Fazal, G.3
Goulet, S.4
Halmos, T.5
Laplante, S.6
Maurice, R.7
Poirier, M.8
Poupart, M.-A.9
Thibeault, D.10
Wernic, D.11
Lamarre, D.12
-
67
-
-
0038343796
-
Product inhibition of the hepatitis C virus NS3 protease
-
DOI 10.1021/bi980313v
-
Steinkühler, C. et al. Product inhibition of the hepatitis C virus NS3 protease. Biochemistry 37, 8899-8905 (1998). (Pubitemid 28299658)
-
(1998)
Biochemistry
, vol.37
, Issue.25
, pp. 8899-8905
-
-
Steinkuhler, C.1
Biasiol, G.2
Brunetti, M.3
Urbani, A.4
Koch, U.5
Cortese, R.6
Pessi, A.7
De Francesco, R.8
-
68
-
-
0347517809
-
Discovery of a novel bicycloproline P2 bearing peptidyl α-ketoamide LY514962 as HCV protease inhibitor
-
DOI 10.1016/j.bmcl.2003.09.074
-
Yip, Y. et al. Discovery of a novel bicycloproline P2 bearing peptidyl alpha-ketoamide LY514962 as HCV protease inhibitor. Bioorg. Med. Chem. Lett. 14, 251-256 (2004). (Pubitemid 38010227)
-
(2004)
Bioorganic and Medicinal Chemistry Letters
, vol.14
, Issue.1
, pp. 251-256
-
-
Yip, Y.1
Victor, F.2
Lamar, J.3
Johnson, R.4
Wang, Q.M.5
Barket, D.6
Glass, J.7
Jin, L.8
Liu, L.9
Venable, D.10
Wakulchik, M.11
Xie, C.12
Heinz, B.13
Villarreal, E.14
Colacino, J.15
Yumibe, N.16
Tebbe, M.17
Munroe, J.18
Chen, S.-H.19
-
69
-
-
9644275435
-
Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells
-
DOI 10.1128/AAC.48.12.4784-4792.2004
-
Lin, K., Kwong, A.D. & Lin, C. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells. Antimicrob. Agents Chemother. 48, 4784-4792 (2004). (Pubitemid 39577685)
-
(2004)
Antimicrobial Agents and Chemotherapy
, vol.48
, Issue.12
, pp. 4784-4792
-
-
Lin, K.1
Kwong, A.D.2
Lin, C.3
-
70
-
-
0037471233
-
Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection
-
Tsantrizos, Y.S. et al. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection. Angew. Chem. 42, 1355-1360 (2003).
-
(2003)
Angew. Chem.
, vol.42
, pp. 1355-1360
-
-
Tsantrizos, Y.S.1
-
71
-
-
0344201903
-
An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus
-
DOI 10.1038/nature02099
-
Lamarre, D. et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426, 186-189 (2003). (Pubitemid 37442587)
-
(2003)
Nature
, vol.426
, Issue.6963
, pp. 186-189
-
-
Lamarre, D.1
Anderson, P.C.2
Bailey, M.3
Beaulieu, P.4
Bolger, G.5
Bonneau, P.6
Bos, M.7
Cameron, D.R.8
Cartier, M.9
Cordingley, M.G.10
Faucher, A.-M.11
Goudreau, N.12
Kawai, S.H.13
Kukolj, G.14
Lagace, L.15
LaPlante, S.R.16
Narjes, H.17
Poupart, M.-A.18
Rancourt, J.19
Sentjens, R.E.20
St. George, R.21
Simoneau, B.22
Steinmann, G.23
Thibeault, D.24
Tsantrizos, Y.S.25
Weldon, S.M.26
Yong, C.-L.27
Llinas-Brunet, M.28
more..
-
72
-
-
7644232426
-
Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients
-
DOI 10.1053/j.gastro.2004.08.002, PII S0016508504013915
-
Hinrichsen, H. et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 127, 1347-1355 (2004). (Pubitemid 39457761)
-
(2004)
Gastroenterology
, vol.127
, Issue.5
, pp. 1347-1355
-
-
Hinrichsen, H.1
Benhamou, Y.2
Wedemeyer, H.3
Reiser, M.4
Sentjens, R.E.5
Calleja, J.L.6
Forns, X.7
Erhardt, A.8
Cronlein, J.9
Chaves, R.L.10
Yong, C.-L.11
Nehmiz, G.12
Steinmann, G.G.13
-
73
-
-
34848881891
-
Ultra-Rapid Cardiotoxicity of the Hepatitis C Virus Protease Inhibitor BILN 2061 in the Urokinase-Type Plasminogen Activator Mouse
-
DOI 10.1053/j.gastro.2007.07.007, PII S0016508507013078
-
Vanwolleghem, T. Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse. Gastroenterology 133, 1144-1155 (2007). (Pubitemid 47494454)
-
(2007)
Gastroenterology
, vol.133
, Issue.4
, pp. 1144-1155
-
-
Vanwolleghem, T.1
Meuleman, P.2
Libbrecht, L.3
Roskams, T.4
De Vos, R.5
Leroux-Roels, G.6
-
74
-
-
33744454875
-
VX950: A tight binding HCV protease inhibitor with a superior sustained inhibitory response in HCV replicon cells
-
Lin, K. et al. VX950: a tight binding HCV protease inhibitor with a superior sustained inhibitory response in HCV replicon cells. Hepatology 38 Suppl, 222 (2003).
-
(2003)
Hepatology
, vol.38
, Issue.SUPPL.
, pp. 222
-
-
Lin, K.1
-
75
-
-
33646446894
-
VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells
-
Lin, K., Perni, R.B., Kwong, A.D. & Lin, C. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrob. Agents Chemother. 50, 1813-1822 (2006).
-
(2006)
Antimicrob. Agents Chemother.
, vol.50
, pp. 1813-1822
-
-
Lin, K.1
Perni, R.B.2
Kwong, A.D.3
Lin, C.4
-
76
-
-
0031024171
-
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
-
DOI 10.1016/S0169-409X(96)00423-1, PII S0169409X96004231
-
Lipinski, C.A., Lombardo, F., Dominy, B.W. & Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3-25 (1997). (Pubitemid 27046991)
-
(1997)
Advanced Drug Delivery Reviews
, vol.23
, Issue.1-3
, pp. 3-25
-
-
Lipinski, C.A.1
Lombardo, F.2
Dominy, B.W.3
Feeney, P.J.4
-
77
-
-
0035897584
-
Amorphous pharmaceutical solids: Preparation, characterization and stabilization
-
DOI 10.1016/S0169-409X(01)00098-9, PII S0169409X01000989
-
Yu, L. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv. Drug Deliv. Rev. 48, 27-42 (2001). (Pubitemid 32454482)
-
(2001)
Advanced Drug Delivery Reviews
, vol.48
, Issue.1
, pp. 27-42
-
-
Yu, L.1
-
78
-
-
84858446501
-
-
Anonymous, International Conference on Harmonization Guidance
-
Anonymous. Stability testing of new drug substances and products (Q1A(R2) (International Conference on Harmonization Guidance, 2003). 〈http://www.fda.gov/downloads/regulatoryinformation/guidances/ucm128204. pdf〉
-
(2003)
Stability Testing of New Drug Substances and Products (Q1A(R2)
-
-
-
79
-
-
33749360242
-
Rapid Decline of Viral RNA in Hepatitis C Patients Treated With VX-950: A Phase Ib, Placebo-Controlled, Randomized Study
-
DOI 10.1053/j.gastro.2006.07.013, PII S0016508506015393
-
Reesink, H.W. et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 131, 997-1002 (2006). (Pubitemid 44498690)
-
(2006)
Gastroenterology
, vol.131
, Issue.4
, pp. 997-1002
-
-
Reesink, H.W.1
Zeuzem, S.2
Weegink, C.J.3
Forestier, N.4
Van Vliet, A.5
Van De Wetering De Rooij, J.6
McNair, L.7
Purdy, S.8
Kauffman, R.9
Alam, J.10
Jansen, P.L.M.11
-
80
-
-
0033834092
-
Need for validation of clinical decision aids: Use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C
-
Imperiale, T.F., Said, A.T., Cummings, O.W. & Born, L.J. Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C. Am. J. Gastroenterol. 95, 2328-2332 (2000).
-
(2000)
Am. J. Gastroenterol.
, vol.95
, pp. 2328-2332
-
-
Imperiale, T.F.1
Said, A.T.2
Cummings, O.W.3
Born, L.J.4
-
81
-
-
34247594930
-
Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor Telaprevir
-
DOI 10.1053/j.gastro.2007.02.037, PII S0016508507003940
-
Sarrazin, C. et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132, 1767-1777 (2007). (Pubitemid 46677938)
-
(2007)
Gastroenterology
, vol.132
, Issue.5
, pp. 1767-1777
-
-
Sarrazin, C.1
Kieffer, T.L.2
Bartels, D.3
Hanzelka, B.4
Muh, U.5
Welker, M.6
Wincheringer, D.7
Zhou, Y.8
Chu, H.9
Lin, C.10
Weegink, C.11
Reesink, H.12
Zeuzem, S.13
Kwong, A.D.14
-
82
-
-
34247565001
-
Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C
-
DOI 10.1002/hep.21774
-
Forestier, N. et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 46, 640-648 (2007). (Pubitemid 47436108)
-
(2007)
Hepatology
, vol.46
, Issue.3
, pp. 640-648
-
-
Forestier, N.1
Reesink, H.W.2
Weegink, C.J.3
McNair, L.4
Kieffer, T.L.5
Chu, H.-M.6
Purdy, S.7
Jansen, P.L.M.8
Zeuzem, S.9
-
83
-
-
34548758435
-
Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients
-
DOI 10.1002/hep.21781
-
Kieffer, T.L. et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46, 631-639 (2007). (Pubitemid 47436107)
-
(2007)
Hepatology
, vol.46
, Issue.3
, pp. 631-639
-
-
Kieffer, T.L.1
Sarrazin, C.2
Miller, J.S.3
Welker, M.W.4
Forestier, N.5
Reesink, H.W.6
Kwong, A.D.7
Zeuzem, S.8
-
84
-
-
46149127335
-
Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients
-
Lawitz, E. et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J. Hepatol. 49, 163-169 (2008).
-
(2008)
J. Hepatol.
, vol.49
, pp. 163-169
-
-
Lawitz, E.1
-
85
-
-
65449171953
-
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection
-
Hézode, C. et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 360, 1839-1850 (2009).
-
(2009)
N. Engl. J. Med.
, vol.360
, pp. 1839-1850
-
-
Hézode, C.1
-
86
-
-
77950817619
-
Telaprevir for previously treated chronic HCV infection
-
erratum 362 1647
-
McHutchison, J. et al. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. 362, 1292-1303; erratum, 362, 1647 (2009).
-
(2009)
N. Engl. J. Med.
, vol.362
, pp. 1292-1303
-
-
McHutchison, J.1
-
87
-
-
0036830454
-
Side effects of therapy of hepatitis C and their management
-
DOI 10.1053/jhep.2002.36810
-
Fried, M.W. Side effects of therapy of hepatitis C and their management. Hepatology 36, S237-S244 (2002). (Pubitemid 35253486)
-
(2002)
Hepatology
, vol.36
, Issue.5
-
-
Fried, M.W.1
-
88
-
-
18844374423
-
How does ribavirin improve interferon-alpha response rates in hepatitis C virus infection?
-
Pawlotsky, J.M. How does ribavirin improve interferon-alpha response rates in hepatitis C virus infection? J. Hepatol. 42, 951-953 (2005).
-
(2005)
J. Hepatol.
, vol.42
, pp. 951-953
-
-
Pawlotsky, J.M.1
-
89
-
-
0031773286
-
Combination therapy of chronic hepatitis C: An important step but not the final goal!
-
DOI 10.1016/S0168-8278(98)80133-5
-
Wedemeyer, H., Caselmann, W.H. & Manns, M.P. Combination therapy of chronic hepatitis C: an important step but not the final goal! J. Hepatol. 29, 1010-1014 (1998). (Pubitemid 28559075)
-
(1998)
Journal of Hepatology
, vol.29
, Issue.6
, pp. 1010-1014
-
-
Wedemeyer, H.1
Caselmann, W.H.2
Manns, M.P.3
-
90
-
-
0031791594
-
Treatment of chronic viral hepatitis
-
Main, J., McCarron, B. & Thomas, H.C. Treatment of chronic viral hepatitis. Antivir. Chem. Chemother. 9, 449-460 (1998). (Pubitemid 28556660)
-
(1998)
Antiviral Chemistry and Chemotherapy
, vol.9
, Issue.6
, pp. 449-460
-
-
Main, J.1
McCarron, B.2
Thomas, H.C.3
-
91
-
-
77950203857
-
Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs)
-
Kieffer, T., Kwong, A. & Picchio, G. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J. Antimicrob. Chemother. 65, 202-212 (2010).
-
(2010)
J. Antimicrob. Chemother.
, vol.65
, pp. 202-212
-
-
Kieffer, T.1
Kwong, A.2
Picchio, G.3
-
92
-
-
27744529265
-
In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061
-
DOI 10.1074/jbc.M506462200
-
Lin, C. et al. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J. Biol. Chem. 280, 36784-36791 (2005). (Pubitemid 41587758)
-
(2005)
Journal of Biological Chemistry
, vol.280
, Issue.44
, pp. 36784-36791
-
-
Lin, C.1
Gates, C.A.2
Rao, B.G.3
Brennan, D.L.4
Fulghum, J.R.5
Luong, Y.-P.6
Frantz, J.D.7
Lin, K.8
Ma, S.9
Wei, Y.-Y.10
Perni, R.B.11
Kwong, A.D.12
-
93
-
-
2342420348
-
In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: Structural analysis indicates different resistance mechanisms
-
DOI 10.1074/jbc.M313020200
-
Lin, C. et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J. Biol. Chem. 279, 17508-17514 (2004). (Pubitemid 38560514)
-
(2004)
Journal of Biological Chemistry
, vol.279
, Issue.17
, pp. 17508-17514
-
-
Lin, C.1
Lin, K.2
Luong, Y.-P.3
Rao, B.G.4
Wei, Y.-Y.5
Brennan, D.L.6
Fulghum, J.R.7
Hsiao, H.-M.8
Ma, S.9
Maxwell, J.P.10
Cottrell, K.M.11
Perni, R.B.12
Gates, C.A.13
Kwong, A.D.14
-
94
-
-
37849032050
-
Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease
-
Zhou, Y. et al. Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease. Antimicrob. Agents Chemother. 52, 110-120 (2008).
-
(2008)
Antimicrob. Agents Chemother.
, vol.52
, pp. 110-120
-
-
Zhou, Y.1
-
95
-
-
34547927078
-
155 variants: Sensitivity to telaprevir (VX-950) and interferon α
-
DOI 10.1074/jbc.M610207200
-
Zhou, Y. et al. Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha. J. Biol. Chem. 282, 22619-22628 (2007). (Pubitemid 47267330)
-
(2007)
Journal of Biological Chemistry
, vol.282
, Issue.31
, pp. 22619-22628
-
-
Zhou, Y.1
Muh, U.2
Hanzelka, B.L.3
Bartels, D.J.4
Wei, Y.5
Rao, B.G.6
Brennan, D.L.7
Tigges, A.M.8
Swenson, L.9
Kwong, A.D.10
Lin, C.11
-
96
-
-
79951630741
-
Long-term follow-up of patients with chronic hepatitis C treated with telaprevir in combination with peginterferon alfa-2a and ribavirin: Interim analysis of the EXTEND study
-
Zeuzem, S. et al. Long-term follow-up of patients with chronic hepatitis C treated with telaprevir in combination with peginterferon alfa-2a and ribavirin: interim analysis of the EXTEND study. Hepatology 52, 436A (2010).
-
(2010)
Hepatology
, vol.52
-
-
Zeuzem, S.1
-
97
-
-
3543125970
-
A long-term latent reservoir for HIV-1: Discovery and clinical implications
-
DOI 10.1093/jac/dkh292
-
Siliciano, J.D. & Siliciano, R.F. A long-term latent reservoir for HIV-1: discovery and clinical implications. J. Antimicrob. Chemother. 54, 6-9 (2004). (Pubitemid 39028960)
-
(2004)
Journal of Antimicrobial Chemotherapy
, vol.54
, Issue.1
, pp. 6-9
-
-
Siliciano, J.D.1
Siliciano, R.F.2
-
98
-
-
51749123143
-
Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects
-
Bartels, D.J. et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J. Infect. Dis. 198, 800-807 (2008).
-
(2008)
J. Infect. Dis.
, vol.198
, pp. 800-807
-
-
Bartels, D.J.1
-
99
-
-
79952308832
-
Clinical virology results from telaprevir Phase 3 study ADVANCE
-
Kieffer, T. et al. Clinical virology results from telaprevir Phase 3 study ADVANCE. Hepatology 52 Suppl, 879A (2010).
-
(2010)
Hepatology
, vol.52
, Issue.SUPPL.
-
-
Kieffer, T.1
-
100
-
-
68549092559
-
Rapid decrease of wild-type hepatitis C virus on telaprevir treatment
-
Adiwijaya, B.S. et al. Rapid decrease of wild-type hepatitis C virus on telaprevir treatment. Antivir. Ther. 14, 591-595 (2009).
-
(2009)
Antivir. Ther.
, vol.14
, pp. 591-595
-
-
Adiwijaya, B.S.1
-
101
-
-
77954598121
-
A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants
-
Adiwijaya, B.S. et al. A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants. PLOS Comput. Biol. 6, e1000745 (2010).
-
(2010)
PLOS Comput. Biol.
, vol.6
-
-
Adiwijaya, B.S.1
-
102
-
-
79959438789
-
Telaprevir for previously untreated chronic hepatitis C virus infection
-
Jacobson, I.M. et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364, 2405-2416 (2011).
-
(2011)
N. Engl. J. Med.
, vol.364
, pp. 2405-2416
-
-
Jacobson, I.M.1
-
103
-
-
80052826527
-
Response-guided telaprevir combination treatment for hepatitis C virus infection
-
Sherman, K.E. et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N. Engl. J. Med. 365, 1014-1024 (2011).
-
(2011)
N. Engl. J. Med.
, vol.365
, pp. 1014-1024
-
-
Sherman, K.E.1
-
104
-
-
79959381354
-
Telaprevir for retreatment of HCV infection
-
Zeuzem, S. et al. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 364, 2417-2428 (2011).
-
(2011)
N. Engl. J. Med.
, vol.364
, pp. 2417-2428
-
-
Zeuzem, S.1
-
105
-
-
79952308832
-
Clinical virology results from telaprevir phase 3 study ADVANCE
-
Kieffer, T. et al. Clinical virology results from telaprevir phase 3 study ADVANCE. Hepatology 52 Suppl, 879A (2010).
-
(2010)
Hepatology
, vol.52
, Issue.SUPPL.
-
-
Kieffer, T.1
-
106
-
-
80053512471
-
Telaprevir in combination with peginterferon alfa-2a and ribavirin increased sustained virologic response rates in treatment-naive patients regardless of race or ethnicity
-
Dusheiko, G.M. et al. Telaprevir in combination with peginterferon alfa-2a and ribavirin increased sustained virologic response rates in treatment-naive patients regardless of race or ethnicity. J. Hepatol. 54 Suppl 1, S167-S168 (2011).
-
(2011)
J. Hepatol.
, vol.54
, Issue.SUPPL. 1
-
-
Dusheiko, G.M.1
-
107
-
-
80755151889
-
Sustained virologic response rates and viral resistance profiles were similar in patients treated with a telaprevir-based regimen regardless of liver fibrosis stage
-
Marcellin, P. et al. Sustained virologic response rates and viral resistance profiles were similar in patients treated with a telaprevir-based regimen regardless of liver fibrosis stage. J. Hepatol. 54 Suppl 1, 1348A (2011).
-
(2011)
J. Hepatol.
, vol.54
, Issue.SUPPL. 1
-
-
Marcellin, P.1
-
108
-
-
84858442180
-
-
Hoffmann-La Roche, Providence, RI
-
Copegus (prescribing information) (Hoffmann-La Roche, Providence, RI, 2010). 〈http://www.gene.com/gene/products/information/pegasys/pdf/copegus- pi.pdf〉
-
(2010)
Copegus (Prescribing Information)
-
-
-
109
-
-
80053339008
-
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
-
Ghany, M.G., Nelson, D.R., Strader, D.B., Thomas, D.L. & Seeff, L.B. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology, 54, 1433-1444 (2011).
-
(2011)
Hepatology
, vol.54
, pp. 1433-1444
-
-
Ghany, M.G.1
Nelson, D.R.2
Strader, D.B.3
Thomas, D.L.4
Seeff, L.B.5
-
110
-
-
0024509701
-
Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
-
Choo, Q.L. et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244, 359-362 (1989).
-
(1989)
Science
, vol.244
, pp. 359-362
-
-
Choo, Q.L.1
-
111
-
-
0030979410
-
Structure of the hepatitis C virus RNA helicase domain
-
DOI 10.1038/nsb0697-463
-
Yao, N. et al. Structure of the hepatitis C virus RNA helicase domain. Nat. Struct. Biol. 4, 463-467 (1997). (Pubitemid 27263599)
-
(1997)
Nature Structural Biology
, vol.4
, Issue.6
, pp. 463-467
-
-
Yao, N.1
Hesson, T.2
Cable, M.3
Hong, Z.4
Kwong, A.D.5
Le, H.V.6
Weber, P.C.7
-
112
-
-
0033539482
-
Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus
-
Bressanelli, S. et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc. Natl. Acad. Sci. USA 96, 13034-13039 (1999).
-
(1999)
Proc. Natl. Acad. Sci. USA
, vol.96
, pp. 13034-13039
-
-
Bressanelli, S.1
-
113
-
-
0034687231
-
Prediction of drug absorption using multivariate statistics
-
E gan, W.J., Merz, K.M. Jr. & Baldwin, J.J. Prediction of drug absorption using multivariate statistics. J. Med. Chem. 43, 3867-3877 (2000).
-
(2000)
J. Med. Chem.
, vol.43
, pp. 3867-3877
-
-
Gan W J, E.1
Merz Jr., K.M.2
Baldwin, J.J.3
-
114
-
-
80055062466
-
Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response
-
published online doi:10.1002/hep.24549 (24 August
-
Muir, A. et al. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology published online, doi:10.1002/hep.24549 (24 August 2011).
-
(2011)
Hepatology
-
-
Muir, A.1
-
115
-
-
79251554986
-
Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or-2b to patients with chronic hepatitis C
-
Marcellin, P. et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or-2b to patients with chronic hepatitis C. Gastroenterology 140, 459-468 (2011).
-
(2011)
Gastroenterology
, vol.140
, pp. 459-468
-
-
Marcellin, P.1
-
116
-
-
65649142019
-
Telaprevir a promising protease inhibitor for the treatment of hepatitis C virus infection
-
Gentile, I., Viola, C., Borgia, F., Castaldo, G. & Borgia, G. Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection. Curr. Med. Chem. 16, 1115-1121 (2009).
-
(2009)
Curr. Med. Chem.
, vol.16
, pp. 1115-1121
-
-
Gentile, I.1
Viola, C.2
Borgia, F.3
Castaldo, G.4
Borgia, G.5
-
117
-
-
65449127754
-
A step forward in therapy for hepatitis C
-
Hoofnagle, J.H. A step forward in therapy for hepatitis C. N. Engl. J. Med. 360, 1899-1901 (2009).
-
(2009)
N. Engl. J. Med.
, vol.360
, pp. 1899-1901
-
-
Hoofnagle, J.H.1
-
118
-
-
67650700013
-
Telaprevir hope on the horizon, getting closer
-
Weisberg, I.S. & Jacobson, I.M. Telaprevir: hope on the horizon, getting closer. Clin. Liver Dis. 13, 441-452 (2009).
-
(2009)
Clin. Liver Dis.
, vol.13
, pp. 441-452
-
-
Weisberg, I.S.1
Jacobson, I.M.2
-
119
-
-
79955669252
-
A new standard of care for the treatment of chronic HCV infection
-
Hofmann, W.P. & Zeuzem, S. A new standard of care for the treatment of chronic HCV infection. Nat. Rev. Gastroenterol. Hepatol. 8, 257-264 (2011).
-
(2011)
Nat. Rev. Gastroenterol. Hepatol.
, vol.8
, pp. 257-264
-
-
Hofmann, W.P.1
Zeuzem, S.2
-
120
-
-
78650805019
-
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naive patients
-
Nelson, D.R. The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naive patients. Liver Int. 31, 53-57 (2011).
-
(2011)
Liver Int.
, vol.31
, pp. 53-57
-
-
Nelson, D.R.1
-
121
-
-
84858450910
-
-
Antiviral Drugs Advisory Committee NDA 201-917 (Cambridge, MA, Vertex Pharmaceuticals Incorporated. 4-28-2011)
-
Antiviral Drugs Advisory Committee. Telaprevir 375-mg film-coated tablet for the treatment of genotype 1 chronic hepatitis C: briefing document. NDA 201-917. (2011). (Cambridge, MA, Vertex Pharmaceuticals Incorporated. 4-28-2011) . 〈http://www. fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/UCM252562. pdf〉
-
(2011)
Telaprevir 375-mg Film-coated Tablet for the Treatment of Genotype 1 Chronic Hepatitis C: Briefing Document
-
-
|